Septic Shock - Pipeline Review, Q2 2011

Description: Septic Shock - Pipeline Review, Q2 2011

Summary

Global Markets Direct's, 'Septic Shock - Pipeline Review, Q2 2011', provides an overview of the Septic Shock therapeutic pipeline. This report provides information on the therapeutic development for Septic Shock, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Septic Shock. 'Septic Shock - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note:- Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Septic Shock.
- A review of the Septic Shock products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Septic Shock pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Septic Shock.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Septic Shock pipeline depth and focus of Septic Shock therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Septic Shock Overview
Therapeutics Development
An Overview of Pipeline Products for Septic Shock
Septic Shock Therapeutics under Development by Companies
Septic Shock Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Pre-Clinical Stage Products
Comparative Analysis
Septic Shock Therapeutics - Products under Development by Companies
Septic Shock Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Septic Shock Therapeutics Development
Medinox, Inc.
AstraZeneca PLC
Cytokine PharmaSciences, Inc.
Atox Bio Inc.
Septic Shock - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
CytoFab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Norathiol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Thiamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Albumin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Norepinephrine + Dobutamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Epinephrine for Septic Shock (University of Versailles) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Levosimendan + Dobutamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Methylene Blue + Nitric Oxide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Terlipressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arginine vasopressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Activated Protein C - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hydrocortisone + Fludrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant human activated protein C + Hydrocortisone + Fludrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dopamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Norepinephrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dopamine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Norepinephrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Insulin + Hydrocortisone + Fludrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Human Insulin + Hydrocortisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Phenylepinephrine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Acetyl-L-Carnitine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AB103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ibuprofen - Drug Profile
Product Description
Mechanism of Action
R&D Progress
L-Carnitine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GIK - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Hypertonic Saline + Terlipressin - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Heparin - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Tetraspan - Drug Profile
Product Description
Mechanism of Action
R&D Progress

Septic Shock Therapeutics – Drug Profile Updates
Septic Shock Therapeutics - Discontinued Products
Septic Shock - Featured News

Apr 09, 2010: XOMA To Present Data On XOMA 052 At American Association of Cancer Research Annual Meeting

Appendix
Methodology
List of Tables
Number of Products Under Development for Septic Shock, Q2 2011
Products under Development for Septic Shock – Comparative Analysis, Q2 2011
Number of Products under Development by Companies, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Comparative Analysis by Pre-Clinical Stage Development, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Medinox, Inc., 2011
AstraZeneca PLC, 2011
Cytokine PharmaSciences, Inc., 2011
Atox Bio Inc., 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Septic Shock Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Septic Shock, Q2 2011
Products under Development for Septic Shock – Comparative Analysis, Q2 2011
Products under Development by Companies, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Pre-Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Ordering:
Order Online - http://www.researchandmarkets.com/reports/1801411/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Septic Shock - Pipeline Review, Q2 2011
Web Address: http://www.researchandmarkets.com/reports/1801411/
Office Code: SCD294L9

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 500</td>
</tr>
<tr>
<td>Electronic (PDF) - Site License</td>
<td></td>
<td>USD 1000</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 1500</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: Mr □ Mrs □ Dr □ Miss □ Ms □ Prof □
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ____________________________________________
Organisation: ____________________________________________
Address: ____________________________________________
City: ____________________________________________
Postal / Zip Code: ____________________________________________
Country: ____________________________________________
Phone Number: ____________________________________________
Fax Number: ____________________________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

<table>
<thead>
<tr>
<th>Description</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Account number</td>
<td>833 130 83</td>
</tr>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World